152 related articles for article (PubMed ID: 31890153)
1. Association between component-resolved diagnosis of house dust mite and efficacy of allergen immunotherapy in allergic rhinitis patients.
Huang Y; Wang C; Lin X; Lou H; Cao F; Li W; Zhang Y; Zhang L
Clin Transl Allergy; 2019; 9():64. PubMed ID: 31890153
[TBL] [Abstract][Full Text] [Related]
2. Specific IgE and IgG4 Profiles of House Dust Mite Components in Allergen-Specific Immunotherapy.
Yang L; Yang Y; Xu Q; Zhang W; Jiang Q; Li W; Wang Y; Ma D; Lin X; Sun B; Zhu R
Front Immunol; 2021; 12():786738. PubMed ID: 35197963
[TBL] [Abstract][Full Text] [Related]
3. [Characteristics of allergen component in dust mite-induced allergic rhinitis patients].
Chen H; Ji P; Yang L; Huang N; Jiang Q; Yang Y; Zhu R
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2023 Jun; 37(6):442-447. PubMed ID: 37253517
[No Abstract] [Full Text] [Related]
4. Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial.
Bożek A; Kołodziejczyk K; Kozłowska R; Canonica GW
Clin Transl Allergy; 2017; 7():43. PubMed ID: 29214012
[TBL] [Abstract][Full Text] [Related]
5. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
6. Effect of mite allergenic components on innate immune response: Synergy of protease (Group 1 & 3) and non-protease (Group 2 & 7) allergens.
Yin SC; Liao EC; Ye CX; Chang CY; Tsai JJ
Immunobiology; 2018; 223(6-7):443-448. PubMed ID: 29398016
[TBL] [Abstract][Full Text] [Related]
7. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
8. House dust mite subcutaneous immunotherapy in Chinese patients with allergic asthma and rhinitis.
Feng M; Zeng X; Li J
J Thorac Dis; 2019 Aug; 11(8):3616-3625. PubMed ID: 31559069
[TBL] [Abstract][Full Text] [Related]
9. Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma.
Jutel M; Brüggenjürgen B; Richter H; Vogelberg C
Allergy; 2020 Aug; 75(8):2050-2058. PubMed ID: 32080856
[TBL] [Abstract][Full Text] [Related]
10. Mite-Allergic Rhinitis: How to Evaluate Clinical Efficacy in Allergen-Specific Immunotherapy Trials?
Pfaar O; Gerth van Wijk R
Curr Treat Options Allergy; 2015; 2(1):1-9. PubMed ID: 25798370
[TBL] [Abstract][Full Text] [Related]
11. The Dermatophagoides pteronyssinus Molecular Sensitization Profile of Allergic Rhinitis Patients in Central China.
Yang Y; Zhu R; Huang N; Li W; Zhang W; Wang Y; Yang L
Am J Rhinol Allergy; 2018 Sep; 32(5):397-403. PubMed ID: 30001632
[TBL] [Abstract][Full Text] [Related]
12. Specific immunoglobulin E and immunoglobulin G4 toward major allergens of house-dust mite during allergen-specific immunotherapy.
Chen J; Zhou Y; Wang Y; Zheng Y; Lai X; Westermann-Clark E; Cho SH; Kong W
Am J Rhinol Allergy; 2017 May; 31(3):156-160. PubMed ID: 28490399
[TBL] [Abstract][Full Text] [Related]
13. New perspectives in allergen specific immunotherapy driven by big trials with house dust mite sublingual SQ
Vitiello G; Maltagliati L; Rossi O
Clin Mol Allergy; 2020; 18():10. PubMed ID: 32536827
[TBL] [Abstract][Full Text] [Related]
14. SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis.
Meteran H; Backer V
Expert Rev Clin Immunol; 2019 Nov; 15(11):1127-1133. PubMed ID: 31584839
[No Abstract] [Full Text] [Related]
15. Allergen Immunotherapy-Induced Immunoglobulin G4 Reduces Basophil Activation in House Dust Mite-Allergic Asthma Patients.
Feng M; Zeng X; Su Q; Shi X; Xian M; Qin R; Li J
Front Cell Dev Biol; 2020; 8():30. PubMed ID: 32154245
[TBL] [Abstract][Full Text] [Related]
16. Clinical effectiveness of house dust mite immunotherapy in mono- versus poly-sensitised patients with allergic rhinitis: a systematic review and meta-analysis.
Kim JY; Hwang D; Jang M; Rhee CS; Han DH
Rhinology; 2021 Aug; 59(4):352-359. PubMed ID: 34180463
[TBL] [Abstract][Full Text] [Related]
17. Long-term benefit after allergen immunotherapy to HDM in elderly patients with allergic rhinitis.
Bożek A; Bogacz-Piaseczyńska A; Miodońska M; Sadowska D
Postepy Dermatol Alergol; 2023 Oct; 40(5):688-692. PubMed ID: 38028423
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
[TBL] [Abstract][Full Text] [Related]
19. Allergic rhinitis: the eligible candidate to mite immunotherapy in the real world.
Ciprandi G; Natoli V; Puccinelli P; Incorvaia C;
Allergy Asthma Clin Immunol; 2017; 13():11. PubMed ID: 28239397
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
